Oncology and Hematology

Episodes 61-75 of 263

• 

  MinuteCE®

  Advancing Prostate Cancer Care: Integrating Guideline Updates and Patient Preferences for Optimal ADT Management of Advanced Prostate Cancer

  • 

    

    Tanya Dorff, MD

    Peer

  • 

    

    Rana McKay, MD

    Peer

  0.75 credits 7 episodes

• 

  RestartResume

  Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer

  MinuteCE®

  Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer

  • 

    

    Ignacio Duran, MD

    Peer

  • 

    

    Wenxin Xu, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer

  MinuteCE®

  Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer

  • 

    

    Ignacio Duran, MD

    Peer

  • 

    

    Sandy Srinivas, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma

  MinuteCE®

  Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma

  • 

    

    Ignacio Duran, MD

    Peer

  • 

    

    Sandy Srinivas, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer

  MinuteCE®

  Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer

  • 

    

    Wenxin Xu, MD

    Peer

  • 

    

    Sandy Srinivas, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy

  MinuteCE®

  Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy

  • 

    

    Wenxin Xu, MD

    Peer

  • 

    

    Sandy Srinivas, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma

  MinuteCE®

  Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma

  • 

    

    Wenxin Xu, MD

    Peer

  • 

    

    Sandy Srinivas, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma

  MinuteCE®

  Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma

  • 

    

    Ignacio Duran, MD

    Peer

  • 

    

    Wenxin Xu, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Emerging targeted therapy combination strategies in genitourinary malignancies

  MinuteCE®

  Emerging targeted therapy combination strategies in genitourinary malignancies

  • 

    

    Ignacio Duran, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Emerging immunotherapy combination strategies in genitourinary malignancies

  MinuteCE®

  Emerging immunotherapy combination strategies in genitourinary malignancies

  • 

    

    Sandy Srinivas, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies

  MinuteCE®

  Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies

  • 

    

    Ignacio Duran, MD

    Peer

  • 

    

    Wenxin Xu, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer

  MinuteCE®

  Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer

  • 

    

    Susana Campos, MD, MPH

    Peer

  • 

    

    Ritu Salani, MD, MBA

    Peer

  1.00 program credits

• 

  RestartResume

  Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer

  MinuteCE®

  Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer

  • 

    

    Nicoletta Colombo, MD

    Peer

  • 

    

    Susana Campos, MD, MPH

    Peer

  1.00 program credits

• 

  RestartResume

  Implementing Guideline-Concordant Care Into the Management of Frontline Patients With Recurrent Endometrial Cancer

  MinuteCE®

  Implementing Guideline-Concordant Care Into the Management of Frontline Patients With Recurrent Endometrial Cancer

  • 

    

    Ritu Salani, MD, MBA

    Peer

  • 

    

    Susana Campos, MD, MPH

    Peer

  1.00 program credits

• 

  RestartResume

  First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer

  MinuteCE®

  First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer

  • 

    

    Nicoletta Colombo, MD

    Peer

  • 

    

    Ritu Salani, MD, MBA

    Peer

  1.00 program credits

• Prev
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• …
• 17
• 18
• Next